Ligand Pharmaceuticals

Yahoo Finance • 4 months ago

Roth analysis: Has volatility created a trigger warning for stocks?

Investing.com - The financial markets have experienced a roller coaster ride of late, prompting analysts at Roth to issue a technical strategy update. Despite ending last week down just 0.04%, the S&P 500's minor dip feels like a victory... Full story

Yahoo Finance • 6 months ago

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

CAPVAXIVEis the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE JUPITER, Fla., June 18, 2024--(BUSINESS WIRE)--Ligand Pharmaceuticals In... Full story

Yahoo Finance • 7 months ago

Ligand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals (NASDAQ:LGND) First Quarter 2024 Results Key Financial Results Revenue: US$31.0m (down 30% from 1Q 2023). Net income: US$86.1m (up 98% from 1Q 2023). EPS: US$4.86 (up from US$2.56 in 1Q 2023). earnings-and-revenue-... Full story

Yahoo Finance • last year

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

SAN DIEGO, December 12, 2023--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provid... Full story

Yahoo Finance • last year

Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium

COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, toda... Full story

Yahoo Finance • last year

Ligand Reports Third Quarter 2023 Financial Results

Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today SAN DIEGO, November 08, 2023--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporate... Full story

Yahoo Finance • last year

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

COLUMBUS, Ohio, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, toda... Full story

Yahoo Finance • last year

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously reta... Full story

Yahoo Finance • last year

Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer

More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapyAbout half never or almost never felt sexual desire or interest in the previous month, particul... Full story

Yahoo Finance • last year

Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms

Results showed that younger age, non-visceral disease, prior tamoxifen and a longer total duration of AI use may be associated with higher baseline vaginal and/or vulvar symptomatologyFindings were presented in a poster at The Menopause So... Full story

Yahoo Finance • last year

Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference

COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, tod... Full story

Yahoo Finance • last year

Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting

One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS,... Full story

Yahoo Finance • last year

Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics

Sermonix used the Tempus TIMETrial® Network to enroll 45% of its ELAINE-2 patients The company is again partnering with Tempus to enroll patients in its Phase 3 ELAINE-3 study COLUMBUS, Ohio, June 26, 2023 (GLOBE NEWSWIRE) -- Sermonix P... Full story

Yahoo Finance • 2 years ago

Ligand Pharmaceuticals (NASDAQ:LGND) Ticks All The Boxes When It Comes To Earnings Growth

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.... Full story

Yahoo Finance • 2 years ago

Bristol Myers (BMY), TSVT Application for Abecma Accepted

Bristol Myers Squibb BMY and partner 2seventy bio, Inc. TSVT announced that the FDA has accepted the companies’ supplemental biologics license application (sBLA) for CAR T cell therapy Abecma (idecabtagene vicleucel). The regulatory body... Full story

Yahoo Finance • 2 years ago

Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy

Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic development Phase 3 study is supported by previously presented ELAINE-1 and ELAINE-2 Phase 2 study resultsSermonix antici... Full story

Yahoo Finance • 2 years ago

Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

Sermonix Pharmaceuticals Inc. ST. LOUIS, March 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecolog... Full story

Yahoo Finance • 2 years ago

Ligand Pharmaceuticals Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Ligand Pharmaceuticals (NASDAQ:LGND) Full Year 2022 Results Key Financial Results Revenue: US$196.2m (down 19% from FY 2021). Net loss: US$5.22m (down by 107% from US$76.4m profit in FY 2021). US$0.31 loss per share (down from US$4.59 pr... Full story

Yahoo Finance • 2 years ago

Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial

COLUMBUS, Ohio, and SAN FRANCISCO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative™ today announced that Sermonix’s investigational next-generation targeted endocrine therapy, las... Full story

Yahoo Finance • 2 years ago

Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women's Sexual Health Annual Meeting 2023

COLUMBUS, Ohio, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ES... Full story